Rufina Kim1, Kerri-Lynn Kelly1, Merle Olson2,3, J Curtis Nickel1. 1. Department of Urology, Queen's University, Kingston, ON, Canada. 2. Department of Biomedical Engineering, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada. 3. VP Research, Chief Medical, Calgary, AB, Canada.
Abstract
INTRODUCTION: We report our early clinical observations on the use of topical meloxicam and lidocaine gel for patients with vulvodynia. METHODS: This is an early experience in participants with a history of vulvodynia evaluated and treated at the Queen's University Pelvic and Bladder Pain Clinic. Combination meloxicam 0.3% and lidocaine 5% were provided to the participants and they were instructed to apply 5 cc to the vulvar area twice daily. Standardized assessment was conducted for each participant before the start of the topical therapy and again at one week, and included Interstitial Cystitis Symptom Index (ICSI), Interstitial Cystitis Problem Index (ICPI), and pain scoring (Likert) for vulvar pain, in addition to a subjective global assessment after a week of treatment. RESULTS: Of the eight participants, six had a subjective improvement in their symptoms with the use of the combination gel. They reported between one- and four-point reductions on the Likert pain scale and mild to moderate improvement of symptoms. Common side effects reported were burning and stinging. CONCLUSIONS: The results from this early experience are promising for a potentially effective topical treatment for vulvodynia.
INTRODUCTION: We report our early clinical observations on the use of topical meloxicam and lidocaine gel for patients with vulvodynia. METHODS: This is an early experience in participants with a history of vulvodynia evaluated and treated at the Queen's University Pelvic and Bladder Pain Clinic. Combination meloxicam 0.3% and lidocaine 5% were provided to the participants and they were instructed to apply 5 cc to the vulvar area twice daily. Standardized assessment was conducted for each participant before the start of the topical therapy and again at one week, and included Interstitial Cystitis Symptom Index (ICSI), Interstitial Cystitis Problem Index (ICPI), and pain scoring (Likert) for vulvar pain, in addition to a subjective global assessment after a week of treatment. RESULTS: Of the eight participants, six had a subjective improvement in their symptoms with the use of the combination gel. They reported between one- and four-point reductions on the Likert pain scale and mild to moderate improvement of symptoms. Common side effects reported were burning and stinging. CONCLUSIONS: The results from this early experience are promising for a potentially effective topical treatment for vulvodynia.